VIVO Complexes Formed by 3-Hydroxy-4-Pyridinones
sets such as (O, O), (O, N), (O, S), (N, N), (N, S), and (S,
S), in which the coordinating atoms belong to different
functional groups.1,4,5 The most common geometry observed
for VIVOL2 complexes is the square-pyramidal, although
distortions toward a trigonal-bipyramidal structure have been
reported for some bidentate ligands.6,7 For VIVOL2 species,
there is the possibility of cis-trans isomerism, where cis is
the bis chelated complex in which the two ligand molecules
adopt an (equatorial-equatorial) and an (equatorial-axial)
arrangement with respect to the VdO bond and one solvent
molecule is coordinated in the fourth equatorial position;
trans is the complex in which both ligand molecules adopt
an (equatorial-equatorial) arrangement with respect to VdO
group.5 Non-oxo (so-called “bare”) VIV centers hold im-
portant biological functions and have been reported for
amavadin8 and for the cofactor in vanadium nitrogenase,9
but only a few such complexes have been fully characterized
in comparison with VIVO species.10
spectroscopic parameters and the degree of distortion toward
the two possible geometries for the complexes.6,7
Vanadium plays an important role in life and one of its
most relevant properties identified thus far is its capacity to
act as an insulin-enhancing agent, either in the form of its
inorganic salts or complexed with organic ligands.3 Among
the several complexes exhibiting the latter properties, [VIVO-
(maltolato)2] (BMOV) has been extensively analyzed from
a chemical and pharmacological point of view.14,15 Up to
this time, many ligands of the 3-hydroxy-4-pyrone type have
been studied, mostly by Orvig and his research group;16
particularly, [VIVO(ethylmaltolato)2] (BEOV) has completed
phase I clinical trials in humans.17
Replacement of the O atom in the pyrone ring of
3-hydroxy-4-pyrone by a N-R group yields 3-hydroxy-4-
pyridinone derivatives.18 Pyridinone ligands can be obtained
by the reaction of pyrones with the appropriate amines and,
like pyrones, can act as anionic bidentate ligands with the
set (O, O) forming stable complexes, mainly with many
trivalent metal ions,19 such as FeIII,20 AlIII,20a,21 GaIII,21b,21c,21e,22
and InIII,22a,23 but also with divalent ions.24 Pyridinones have
Several spectroscopic techniques are available for the
characterization of VIV species.11 EPR spectroscopy (mainly
in conjunction with UV/vis) has revealed itself to be the most
powerful tool not only for structurally characterizing VIV
complexes12,13 but also for identifying the presence of isomers
in certain solvents and establishing relationships between the
(14) (a) Caravan, P.; Gelmini, L.; Glover, N.; Herring, F. G.; McNeill, J.
H.; Rettig, S. J.; Setyawati, I. A.; Shutter, E.; Sun, Y.; Tracey, A. S.;
Yuen, V. G.; Orvig, C. J. Am. Chem. Soc. 1995, 117, 12759-12770.
(b) Sun, Y.; James, B. R.; Rettig, S. J.; Orvig, C. Inorg. Chem. 1996,
35, 1667-1673. (c) Hanson, G. R.; Sun, Y.; Orvig, C. Inorg. Chem.
1996, 35, 6507-6512.
(15) (a) McNeill, J. H.; Yuen, V. G.; Hoveyda, H. R.; Orvig, C. J. Med.
Chem. 1992, 35, 1489-1491. (b) Setyawati, I. A.; Thompson, K. H.;
Yuen, V. G.; Sun, Y.; Battell, M.; Lyster, D. M.; Vo, C.; Ruth, T. J.;
Zeisler, S.; McNeill, J. H.; Orvig, C. J. Appl. Physiol. 1998, 84, 569-
575.
(16) (a) Yuen, V. G.; Caravan, P.; Gelmini, L.; Glover, N.; McNeill, J. H.;
Setyawati, I. A.; Zhou, Y.; Orvig, C. J. Inorg. Biochem. 1997, 68,
109-116. (b) Song, B.; Saatchi, K.; Rawji, G. H.; Orvig, C. Inorg.
Chim. Acta 2002, 339, 393-399. (c) Monga, V.; Thompson, K. H.;
Yuen, V. G.; Sharma, V.; Patrick, B. O.; McNeill, J. H.; Orvig, C.
Inorg. Chem. 2005, 44, 2678-2688. (d) Saatchi, K.; Thompson, K.
H.; Patrick, B. O.; Pink, M.; Yuen, V. G.; McNeill, J. H.; Orvig, C.
Inorg. Chem. 2005, 44, 2689-2697.
(17) Thompson, K. H.; Liboiron, B. D.; Sun, Y.; Bellman, K. D. D.;
Setyawati, I. A.; Patrick, B. O.; Karunaratne, V.; Rawji, G.; Wheeler,
J.; Sutton, K.; Bhanot S.; Cassidy, C.; McNeill, J. H.; Yuen, V. G.;
Orvig, C. J. Biol. Inorg. Chem. 2003, 8, 66-74.
(1) Crans, D. C.; Smee, J. J.; Gaidamauskas, E.; Yang, L. Chem. ReV.
2004, 104, 849-902.
(2) Butler, A.; Walker, J. V. Chem. ReV. 1993, 93, 1937-1944.
(3) (a) Shechter, Y.; Karlish, S. J. D. Nature 1980, 286, 556-558. (b)
Shechter, Y.; Goldwaser, I.; Mironchik, M.; Fridkin, M.; Gefel, D.
Coord. Chem. ReV. 2003, 237, 3-11. (c) Thompson, K. H.; McNeill,
J. H.; Orvig, C. Chem. ReV. 1999, 99, 2561-2571 and references
therein. (d) Thompson, K. H.; Orvig, C. Coord. Chem. ReV. 2001,
219-221, 1033-1053 and references therein.
(4) Crans, D. C.; Tracey, A. S. In Vanadium Compounds: Chemistry,
Biochemistry, and Therapeutic Applications; Tracey, A. S.; Crans, D.
C., Eds.; ACS Symposium Series 711; American Chemical Society:
Washington, DC, 1998; Vol. 31, pp 2-29.
(5) Garribba, E.; Micera, G.; Lodyga-Chruscinska, E.; Sanna, D. Eur. J.
Inorg. Chem. 2006, 2690-2700.
(6) Cornman, C. R.; Geisre-Bush, K. M.; Rowley, S. R.; Boyle, P. D.
Inorg. Chem. 1997, 36, 6401-6408.
(7) Garribba, E.; Micera, G.; Panzanelli, A.; Sanna, D. Inorg. Chem. 2003,
42, 3981-3987.
(18) Although there are several pyridinone ligands that depend on the
position of the keto and hydroxy groups (1-hydroxy-2-pyridinones or
1,2-HP, 2-hydroxy-3-pyridinones or 2,3-HP, for example), in this work
the word pyridinones will be used to indicate 3-hydroxy-4-pyridinones
(3,4-HP).
(8) (a) Bayer, E.; Koch, E.; Anderegg, G. Angew. Chem., Int. Ed. 1987,
26, 545-546. (b) Carrondo, M. A. A. F. de C. T.; Duarte, M. T. L.
S.; Costa Pessoa, J.; Silva, J. A. L.; Frau´sto da Silva, J. J. R.; Vaz, M.
C. T. A.; Vilas-Boas, L. F. J. Chem. Soc., Chem. Commun. 1988,
1158-1159. (c) Carrondo, M. A. A. F. de C. T.; Duarte, M. T. L. S.;
Frau´sto da Silva, J. J. R. Struct. Chem. 1992, 3, 113-119. (d) Smith,
P. D.; Berry, R. E.; Harben, S. M.; Beddoes, R. L.; Helliwell, M.;
Collison, D.; Garner, C. D. J. Chem. Soc., Dalton Trans. 1997, 4509-
4516. (e) Berry, R. E.; Armstrong, E. M.; Beddoes, R. L.; Collison,
D.; Ertok, S. N.; Helliwell, M.; Garner, C. D. Angew. Chem., Int. Ed.
1999, 38, 795-797.
(19) Santos, M. A. Coord. Chem. ReV. 2002, 228, 187-203 and references
therein.
(20) (a) Tsai, W.-C.; Ling, K.-H. J. Chin. Biochem. Soc. 1973, 2, 70-86.
(b) Scarrow, R. C.; Riley, P. E.; Abu-Dari, K.; White, D. L.; Raymond,
K. N. Inorg. Chem. 1985, 24, 954-967. (c) Clarke, E. T.; Martell, A.
E.; Reibenspies, J. Inorg. Chim. Acta 1992, 196, 177-183. (d) Dobbin,
P. S.; Hider, R. C.; Hall, A. D.; Taylor, P. D.; Sarpong, P.; Porter, J.
B.; Xiao, G.; van der Helm, D. J. Med. Chem. 1993, 36, 2448-2458.
(21) (a) Nelson, W. O.; Rettig, S. J.; Orvig, C. J. Am. Chem. Soc. 1987,
109, 4121-4123. (b) Nelson, W. O.; Karpishin, T. B.; Rettig, S. J.;
Orvig, C. Inorg. Chem. 1988, 27, 1045-1051. (c) Nelson, W. O.;
Rettig, S. J.; Orvig, C. Inorg. Chem. 1989, 28, 3153-3157. (d)
Clevette, D. J.; Nelson, W. O.; Nordin, A.; Orvig, C.; Sjoberg, S.
Inorg. Chem. 1989, 28, 2079-2081. (e) Zhang, Z.; Rettig, S. J.; Orvig,
C. Inorg. Chem. 1991, 30, 509-515. (f) Florence, A. L.; Gauthier,
A.; Ward, R. J.; Crichton, R. R. Neurodegeneration 1995, 4, 449-
455.
(22) (a) Clevette, D. J.; Lyster, D. M.; Nelson, W. O.; Rihela, T.; Webb,
G. A.; Orvig, C. Inorg. Chem. 1990, 29, 667-672. (b) Santos, M. A.;
Grazina, R.; Neto, A. Q.; Cantino, G.; Gano, L.; Patricio, L. J. Inorg.
Biochem. 2000, 78, 303-311.
(23) Matsuba, C. A.; Nelson, W. O.; Rettig, S. J.; Orvig, C. Inorg. Chem.
1988, 27, 3935-3939.
(9) (a) Robson, R. L.; Eady, R. R.; Richardson, T. J.; Miller, R. W.;
Hawkins, M.; Postgate, J. R. Nature 1986, 322, 388-390. (b) Eady,
R. R. In Metal Ions in Biological Systems; Sigel, A.; Sigel, H., Eds.;
Marcel Dekker: New York, 1995; Vol. 31, pp 363-405 and references
therein.
(10) Morgenstern, B.; Steinhauser, S.; Hegetschweiler, K.; Garribba, E.;
Micera, G.; Sanna, D.; Nagy, L. Inorg. Chem. 2004, 43, 3116-3126
and references therein.
(11) (a) Garner, C. D.; Collison, D.; Mabbs, F. E. In Metal Ions in
Biological Systems; Sigel, A.; Sigel, H., Eds.; Marcel Dekker: New
York, 1995; pp 617-670. (b) Micera, G.; Sanna, D. In Vanadium in
the EnVironment Part 1: Chemistry and Biochemistry; Nriagu, J. O.
Ed.; Wiley: New York, 1998; pp 131-166.
(12) Smith, T. S., II; LoBrutto, R.; Pecoraro, V. L. Coord. Chem. ReV.
2002, 228, 1-18.
(13) Mabbs, F. A. Chem. Soc. ReV. 1993, 313-324.
Inorganic Chemistry, Vol. 45, No. 20, 2006 8087